MAS825 for COVID-19: real-time analysis

Download Image

Post

c19early.org

MAS825 for COVID-19

1 study with 138 patients

Serious outcome risk

MAS825

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 MAS825 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−16%

Mortality (1)−16%

RCTs (1)−16%

Late (1)−16%

00.511.5+

← MAS825
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 20 2023	Hakim et al., Clinical and Experimental Immunology, doi:10.1093/cei/uxad065	Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function
Jun 20 2023	16% higher mortality (p=0.59) and 7% worse recovery (p=0.7). RCT 138 hospitalized COVID-19 patients with pneumonia showing no significant difference in mortality or APACHE II scores with MAS825 (anti-IL-1β/IL-18 monoclonal antibody) compared to placebo.